Schizophrenia is a chronic brain condition that causes severe, incapacitating psychotic episodes in sufferers. The World Health Organization (WHO) estimates that the condition affects approximately 24 million individuals worldwide. Schizophrenia Therapeutic Market is distinguished by the presence of auditory or visual hallucinations, which are accompanied by fixed, erroneous delusions. The two characteristics are frequently noticed in individuals in conjunction with learning and cognitive problems. Despite the emergence of atypical antipsychotics over the last two decades, existing treatments for schizophrenia do not address negative and cognitive symptoms associated with the disorder. Negative symptoms are deviations from normal behaviour and feelings that can be misdiagnosed as other diseases such as depression. LAI antipsychotics are expected to gain popularity, according to Global Data. Together with planned novel medicines that aim increased efficacy in negative- and cognitive-predominant patients, the market will expand from 2012 to 2022.
Read more; - https://cmi-blogger.blogspot.com/2022/09/schizophrenia-therapeutic-market-by.html
